Biotechnology Business Sector

The biotechnology business sector focuses on developing innovative products and technologies that improve healthcare, agriculture, and environmental sustainability through genetic engineering, molecular biology, and bioinformatics. A CEO in this sector drives strategic growth, fosters research and development, and steers company performance by securing funding, managing regulatory compliance, and delivering cutting-edge solutions that enhance market competitiveness.

Amgen

Robert A. Bradway's estimated net worth of around $125 million primarily derives from his long tenure as CEO and Chairman of Amgen, combined with substantial annual compensation, stock grants, and accumulated shareholdings in the biotechnology company.

Genentech

Alexander Hardy's estimated net worth of around $30 million primarily results from his executive compensation, stock awards, and performance bonuses accrued during his tenure as CEO of Genentech and Roche Pharmaceuticals.

Biogen

Christopher Viehbacher's estimated net worth of around $50 million stems from his executive compensation at Biogen and previous leadership roles at Sanofi and GlaxoSmithKline, including base salary, bonuses, stock awards, and long-term incentives.

Gilead Sciences

Daniel O'Day's estimated net worth of around $80 million primarily derives from his executive compensation, stock awards, and performance bonuses as CEO of Gilead Sciences, as well as his prior leadership roles at Roche.

Regeneron Pharmaceuticals

Leonard S. Schleifer's estimated net worth of around $1.5 billion is primarily derived from his significant equity holdings and long-standing leadership as CEO and co-founder of Regeneron Pharmaceuticals.

Moderna

Stephane Bancel's estimated net worth of around $4 billion primarily stems from his significant equity stake in Moderna, which surged in value due to the global success of the company's mRNA COVID-19 vaccine.

Illumina

Jacob Thaysen's estimated net worth of around $20 million is derived from his executive compensation, stock ownership, and previous leadership roles in biotech companies, including his current CEO position at Illumina.

Vertex Pharmaceuticals

Reshma Kewalramani, current CEO of Vertex Pharmaceuticals, has a net worth estimated at around $65 million primarily due to her executive compensation, stock awards, and long-term incentives linked to Vertex's market performance.

Alexion Pharmaceuticals

Marc Dunoyer, CEO of Alexion Pharmaceuticals, has a net worth estimated at $40 million due to his long-term executive roles at global pharmaceutical firms like AstraZeneca and significant equity awards, bonuses, and salary packages.

CRISPR Therapeutics

Samarth Kulkarni's estimated net worth of around $60 million derives primarily from his executive compensation, equity holdings, and stock options accumulated as CEO of CRISPR Therapeutics.

Bio-Rad Laboratories

Norman Schwartz, CEO of Bio-Rad Laboratories, has an estimated net worth of around $150 million due to his long tenure, significant equity holdings, and substantial annual compensation packages from the company.

Novozymes

Ester Baiget, current CEO of Novozymes, has an estimated net worth of around $10 million, primarily due to her executive compensation package, long-term incentive plans, and accumulated stock options granted by the company and previous roles at DowDuPont.

Qiagen

Thierry Bernard's estimated net worth of around $10 million is attributed to his executive compensation, performance-based stock awards, and long-term incentives accrued during his tenure as CEO of Qiagen N.V.

BioNTech

Ugur Sahin's estimated net worth of $2.4 billion stems primarily from his significant equity stake in BioNTech, which surged in valuation following the global success of its mRNA COVID-19 vaccine and corresponding IPO.

Alnylam Pharmaceuticals

Yvonne Greenstreet's estimated net worth of $50 million stems largely from her executive compensation, significant stock awards, and equity holdings accrued since joining Alnylam Pharmaceuticals, where she has held key leadership roles including CEO.

Sarepta Therapeutics

Douglas S. Ingram's estimated net worth of around $80 million stems primarily from his executive compensation, equity holdings, and stock options as CEO of Sarepta Therapeutics, a leading biotechnology company focused on genetic medicines for rare diseases.

Myriad Genetics

Paul J. Diaz's estimated net worth of around $25 million primarily stems from his executive compensation, stock awards, and performance incentives as CEO of Myriad Genetics, along with prior earnings from leadership roles at other healthcare companies.

Seagen (formerly Seattle Genetics)

David R. Epstein's estimated net worth of around $150 million primarily stems from his executive compensation, bonuses, and substantial stock holdings acquired through his leadership roles at Novartis, Intercept Pharmaceuticals, and as CEO of Seagen.

Bluebird Bio

Andrew Obenshain's net worth, estimated at around $5 million, stems primarily from his salary, stock options, and equity grants as CEO of Bluebird Bio, along with his prior executive roles in the biotech industry.

Sangamo Therapeutics

Sandy Macrae, current CEO of Sangamo Therapeutics, has an estimated net worth of around $10 million primarily due to his executive compensation, stock holdings, and equity awards from Sangamo and previous leadership roles in the biotech sector.

Agilent Technologies

Padraig McDonnell's estimated net worth of around $20 million stems from his executive compensation, stock awards, and incentive plans as CEO and former senior executive roles at Agilent Technologies.

Thermo Fisher Scientific

Marc N. Casper's estimated net worth of around $300 million stems primarily from his long-term executive leadership at Thermo Fisher Scientific, where substantial compensation packages, stock awards, and share appreciation have contributed to his wealth.

PerkinElmer

Prahlad Singh's estimated net worth of around $40 million is primarily attributed to his compensation package as CEO of PerkinElmer, which includes salary, bonuses, stock awards, and accumulated equity holdings.

Editas Medicine

Gilmore O'Neill's estimated net worth of around $10 million is primarily derived from his compensation, stock awards, and equity holdings as CEO of Editas Medicine, as well as previous executive roles at Biogen and Sarepta Therapeutics.

Twist Bioscience

Emily M. Leproust's estimated net worth of around $60 million primarily derives from her equity holdings and compensation as CEO and co-founder of Twist Bioscience, a publicly traded company specializing in synthetic DNA production.

Greenlight Biosciences

Peter Kolchinsky's estimated net worth of around $150 million stems from his founding role and equity in RA Capital Management, a prominent life sciences investment firm, as well as his leadership and stock holdings as current CEO of Greenlight Biosciences.

Precision BioSciences

Michael Amoroso's estimated net worth of around $5 million derives primarily from his executive compensation, stock options, and equity holdings in Precision BioSciences (NASDAQ: DTIL), alongside prior leadership roles in other biotech firms.

Promega Corporation

Bill Linton's estimated net worth of around $500 million stems from his founding stake and ongoing leadership in Promega Corporation, a major global supplier of biotechnology and life science research products.

Charles River Laboratories

James C. Foster, CEO of Charles River Laboratories, has accrued an estimated net worth of around $250 million primarily through decades-long executive leadership, substantial equity holdings, stock grants, and performance-based compensation tied to the company's sustained market growth and acquisitions.

Catalent

Alessandro Maselli's estimated net worth of around $10 million primarily stems from his executive compensation, stock ownership, bonuses, and long-term incentives as CEO of Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.